Pear Therapeutics, Inc. reaffirmed revenue guidance for the full year 2022. For the year, reaffirmed its $22 million revenue guidance.
Pear Therapeutics, Inc.
Equities
PEAR
US7047231052
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |